 buy pt initi buy pt base meaning rebound ep
inc hold pt initi hold rate pt base potenti lower
appli dna scienc inc apdn buy pt preliminari result miss estim expect linearx
becom primari focu reiter buy analyst anthoni vendetti full summari
time restaur inc gtim buy pt warn still construct bad daddi
overal margin growth maintain buy pt analyst stephen anderson full summari
adial adil buy pt expand beyond alcohol use disord opioid disord
corpor event call maxim salesperson inform
custom inc cover diana ndr boston ceo jay sidhu cfo carla leibold tue
turtl beach corpor hear cover chokshi ndr san francisco san jose ceo juergen stark
pitney bow inc cover klee ndr milwauke madison cfo stan sutula tue dec
pitney bow inc cover klee ndr chicago cfo stan sutula vice-president investor relat adam david
investor relat june vecellio wed dec
maxim women health kol dinner last week held dinner
discuss clinic insight key opinion leader kol field
well upcom product ceo bioscienc agil
therapeut event highlight trend contracept space
twirla ovapren may fit marketplac
current women contracept report would prefer low-
dose combin hormon contracept chc mani opt non-
kol mention women priorit safeti conveni
patient complianc crucial aspect contracept perform
mobil app track timelin chang product
posit impact complianc clinic trial
translat real world
dar ovapren fit grow trend women avers
hormone-bas method would simpli prefer hormone-fre ring
avail marketplac
agil twirla may abl provid safer black low-dos
ethinyl estradiol vs patch altern xulan nr
mobil app twirla part plan market campaign
conclus contracept larg market gener rx sale
us compani pois address two larg market opportun
line current trend within contracept space await dar
ovapren phase pct data agil full protocol compar wear
studi twirla vs xulan import catalyst
bioscienc develop ovapren hormone-fre monthli vagin
contracept ring creat spermiostat environ silicon matrix
releas ascorb acid ferrou glucon effect cut tail
sperm non-braid multi-fila mesh barrier design block sperm
attempt enter cervic canal two compon could produc similar
efficaci diaphragm short-act hormon option vagin ring pill
patch ovapren may meet women prefer characterist long-act
hormone-fre birth control current avail method ovapren devic
pma pathway phase mid-stag post-coit clinic trial pct on-going data
agil develop twirla low-dos weekli chc transderm
patch contain combin estrogen ethinyl estradiol progestin
levonorgestrel made worn buttock abdomen upper torso seven
day straight chang week three consecut week one patch-fre
week time woman withdraw bleed use correctli twirla
effect rate well-toler mild side effect nausea
headach agil incorpor proprietari skinfus adhes technolog
patch design final hurdl re-fil two-week random crossov
wear studi healthi women less
subject wear twirla
xulan patch first week switch patch second week
compani announc type meet fda took place week
dec meet minut becom avail januari point
compani give addit color crossov wear studi trial design plan
complet studi resubmit twirla nda put potenti
approv
click full note
initi buy pt base meaning
rebound ep strateg action address
believ recent backlog growth sale lower-margin busi
first posit oper ep four quarter loss altogeth
suggest meaning rebound ep
alreadi complet signific restructur action last two
year includ discontinu dividend payment revis coven
compani credit facil sell non-cor busi
beyond forecast focu air qualiti fluid handl end-
market help compani meet financi target
base achiev target forecast ep
slightli last peak ep take
account cyclic risk end market
mani end market higher growth year
other believ sourc sustain demand natur
ga power plant replac old equip decreas air pollut
believ share continu outperform anticip
meaning rebound ep potenti proactiv
environment stanc futur politician also note two insid
purchas share last month base public file
forecast meaning rebound ep factor declin power
plant equip work note revenu
natur ga power plant work coal-fir power plant forecast
slowdown natur ga power plant construct one off-set
newbuild declin replac equip old natur ga power plant
forecast flat demand natur ga power plant complet
sale coal-fir power plant busi china zhongli factor
declin revenu remain coal-fir power plant busi forecast
market revenu
growth end market off-set declin power gener work
forecast growth three six end market believ altogeth
revenu three end market midstream oil ga includ
ga separ equip industri solut air qualiti equip fluid
handl separ forecast flat refin market growth order
trail end increas prior year
alreadi start improv ebitda margin compani histor
achiev ebitda margin target rang increas
oper ebitda margin exclud share-bas compens expens
one-tim charg prior year first annual
improv margin sinc
revenu growth rebound ebitda ep support
valuat ep forecast initi coverag buy
rate price target base ep estim
averag forward pe multipl peer group includ much
larger industri compani lower ep growth rate peer group also
forward pe ratio peer group rang target pe ratio
slightli higher current forward pe ratio base forecast
oper ep quadrupl increas
click full note
initi hold rate pt base
potenti lower market growth
although work govern project recess
believ stock price may struggl achiev meaning upsid
stock market price end current streak impress
believ replac servic old equip insid exist build
govern sustain sourc work help prevent
drastic declin ep event recess
also forecast continu gener consist free cash flow
cash debt
still compar averag oper incom growth
potenti lower annual oper incom growth base
forecast may limit upsid stock price
one-year invest horizon
evid acceler growth nonresidenti construct key
driver earn could catalyst upward ep revis
scale experi continu help work larg complex
build factori govern facil identifi anoth
compani similar simultan provid reliabl construct
mainten multi-stori build elev floor factori
cover area five acr owner facil usual prefer
work establish compani access larg base
experienc employe exist union agreement good safeti track record
experi work similar structur also owner may work
project
govern work support ep econom growth slow work
airport highway light mass transit signal system water distribut facil
among government-rel project instanc work light
system new governor mario cuomo bridg new york also sinc almost
half revenu come servic work keep make money
construct finish provid mainten repair
consist free cash flow lead acquisit buyback market
growth declin believ continu gener consist free cash flow
compani cash flow oper less capit expenditur
million everi year sinc net cash million futur free cash
flow believ continu repurchas share complet acquisit
free cash flow support valuat ep forecast
initi coverag hold rate price target base
ep estim target pe multipl premium averag
multipl smaller subcontractor base broader geograph reach
industri exposur cheaper cost capit ep estim
current consensu forecast base outlook nonresidenti construct
new commerci build decreas
click full note
warn still construct bad
daddi overal margin growth maintain buy pt
maintain buy rate price target time restaur
gtim follow releas full septemb result yesterday
gtim incur loss per share though loss
narrow consensu revenu also beat consensu
howev manag warn slow start due primarili harsh
weather bad daddi core north carolina market time core
manag also dial back unit develop slightli bad
daddi aggress develop though expect
acceler
nevertheless still believ gtim compel valuat growth
margin expans thesi remain intact
ep loss actual vs loss maxim loss street three
adjust ebitda actual vs maxim street three
revenu actual vs maxim street two analyst
comp time bad daddi alreadi provid octob
adjust ebitda margin actual vs maxim
adjust ebitda vs maxim street prior
guidanc revis estim
revenu reduc vs maxim street prior
guidanc revis estim
time ttm sale revis vs maxim
prior guidanc revis estim though expect comp
turn posit
bad daddi ttm sale revis vs maxim
prior guidanc revis estim
new unit manag expect open bad daddi restaur
vs maxim prior guidanc model open six bad daddi
restaur also expect new unit time unchang
recommend buy post-earn pullback believ gtim
compel valuat gtim trade ttm ebitda multipl
gtim post-ipo averag argu valuat account
bad daddi desir growth combin valuat model use
base valuat year use ebitda multipl time
ebitda multipl bad daddi use model arriv unchang
click full note
linearx becom primari focu reiter buy
today market open apdn report preliminari sept
revenu loss per share figur miss estim
lower textil revenu significantli weigh revenu growth
partial off-set higher contract manufactur revenu
cannabi pharmaceut custom
believ linearx remain key futur growth driver compani
begin develop pcr technolog car-t therapi deliveri method
biotherapeut market
reduc estim
releas week follow confer
call week
bottom line would continu buyer apdn despit report weaker-than-
expect preliminari sept result believ apdn dna mark
solut signaturet certaint possess technolog edg address major
suppli chain manipul issu across variou industri howev believ apdn
devot signific resourc toward biotherapeut busi linearx order
grow segment linearx potenti disrupt cost
effect car-t deliveri methodolog pcr technolog give us confid
abil penetr highli competit space remain earli develop
stage report date decemb detail opportun
therefor given signific growth opportun across multipl industri vertic
reiter buy rate price target
preliminari result today market open apdn report
preliminari revenu roughli y/i estim
consensu loss per share compar
wider-than estim consensu
wider-than expect loss per share primarili attribut increas
total oper expens higher oper expens relat higher
stock-bas compens well research develop expenditur
lower estim due weaker-than-expect preliminari result
lower revenu estim
respect also widen lower
ep estim
respect
valuat apdn current trade ev/revenu estim compar
peer averag deriv price target deploy dcf
analysi discount rate termin growth rate impli share trade
ev/revenu estim believ justifi due larg
total address market counterfeit protect linearx potenti penetr
biotherapeut
click full note
expand beyond alcohol use disord opioid
adial announc compani expand activ around lead
asset beyond alcohol use disord aud includ potenti use
patient opioid use disord oud
tackl drug overdos market accord cdc
us die drug overdos least two-third
link opioid cocain meth even heroin synthet opioid like
work ultra-low dose approv drug
ondansetron market zofran target receptor block
action serotonin receptor locat area
brain relat dopamin reward-learn axi block
ondansetron may reduc compulsion/desir drink alcohol
conclus though timelin second indic yet
disclos view strateg posit adial suggest
could platform play multipl addict disord share
initi first aud well plan oud
fentanyl opioid crisi us still grip opioid crisi accord
cdc repres record year overdos death
american lose live opioid primari culprit
overdos case oxycodon heroin histor major threat
synthet opioid fentanyl recent emerg major contributor surpass
heroin number one caus od death us latest number
cdc link place number death involv fentanyl ahead
heroin fentanyl synthet opioid
potent heroin mean milligram enough lethal peopl
potenc come chemic structur fentanyl move brain
faster morphin activ by-product heroin bind tightli -opioid
receptor brain also mean fentanyl overdos harder treat
singl dose naloxon narcan often enough reviv od patient sinc
strong often-tim heroin lace fentanyl produc stronger product
user may complet unawar
 precis treatment aud opioid use ultra-low
dose approv drug ondansetron market zofran develop
treatment aud ondansetron target receptor block action
serotonin may reduc compulsion/desir drink alcohol also
involv opioid addict may applic patient opioid use
disord oud adial identifi specif genet variant receptor
transport may predict patient benefit treatment
studi patient particular genotyp experienc reduc drink
per drink day reduct frequenc drink day
compar day abstin decreas percentag heavi
drink day pdhd vs genotyp
benefit refer phase genotyp studi aud
subject depend geograph locat harbor genotyp avail drug
aud requir abstin treatment come unpleas side effect
aud subject combin eu larg market opportun
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
